KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Total Debt (2016 - 2020)

Neogenomics' Total Debt history spans 11 years, with the latest figure at $95.6 million for Q1 2020.

  • For Q1 2020, Total Debt rose 1.85% year-over-year to $95.6 million; the TTM value through Mar 2020 reached $95.6 million, up 1.85%, while the annual FY2019 figure was $96.8 million, 652.19% up from the prior year.
  • Total Debt reached $95.6 million in Q1 2020 per NEO's latest filing, down from $96.8 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $99.3 million in Q3 2019 to a low of $5.0 million in Q2 2019.
  • Average Total Debt over 5 years is $55.7 million, with a median of $52.9 million recorded in 2016.
  • Peak YoY movement for Total Debt: tumbled 89.88% in 2018, then soared 1275.6% in 2019.
  • A 5-year view of Total Debt shows it stood at $73.9 million in 2016, then decreased by 4.78% to $70.4 million in 2017, then plummeted by 81.71% to $12.9 million in 2018, then surged by 652.19% to $96.8 million in 2019, then fell by 1.26% to $95.6 million in 2020.
  • Per Business Quant, the three most recent readings for NEO's Total Debt are $95.6 million (Q1 2020), $96.8 million (Q4 2019), and $99.3 million (Q3 2019).